Drug Trial Radar · NCT05668026
Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Apr 1, 2024
Primary completion
Mar 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- University of AarhusAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Peter Doherty Institute for Infection and Immunity; Walter and Eliza Hall Institute of Medical Research; The Alfred; Aarhus University Hospital
- First posted
- Dec 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In summary, there is a compelling rationale for investigating venetoclax as an intervention to sensitise virus-expressing cells to apoptosis and thereby reduce the size of the latent HIV reservoir. While this concept may ultimately need to be tested in the setting of concomitant latency reversal, the investigators propose to initially establish the safety of venetoclax in PLWH on ART. The investigators will use this study to also investigate effects of venetoclax monotherapy on proapoptotic pathways, immune effector function and HIV persistence in PLWH on ART and through these studies establish the rationale for subsequent studies testing venetoclax in combination with an LRA.
Conditions
- HIV-1-infection
Interventions
VenetoclaxDrug
In this study participants will receive venetoclax 200 mg, 400 mg or 600 mg once daily for 14 days in the dose-escalation phase. In the expansion cohort, the selected max-tolerated dose will be given for three cycles, each consisting of venetoclax daily for 14 days followed by 21 days off.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the safety of venetoclax in PLWH on ARTTime frame: 0-140 days
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
The Alfred
Melbourne, Melbourne, Australia · Recruiting
Aarhus University Hospital
Aarhus, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.